Overview

Symptomatic Treatment Of Patients With Neuropathic Pain With LYRICA

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
A Non-Interventional, Post-Marketing Surveillance (NI-PMS) study whose objectives were to assess the impact of pregabalin on subjects' pain, quality of sleep, and their general wellbeing, as well as the tolerance and safety of pregabalin in subjects with neuropathic pain.
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Pregabalin